2023年度卵巢癌药物治疗研究进展  

Progress in medical treatment of ovarian cancer in 2023

作　　者：杨洁 向阳 Yang Jie;Xiang Yang(Department of Obstetrics and Gynecology,National Clinical Research Center for Obstetric&Gynecologic Diseases,Peking Union Medical College Hospital,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院妇产科,国家妇产疾病临床医学研究中心,北京100730

出　　处：《肿瘤综合治疗电子杂志》2024年第1期58-62,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：中央高水平医院临床科研业务费资助项目(2022-PUMCH-B-083)。

摘　　要：卵巢癌作为女性生殖系统恶性程度较高的常见肿瘤,严重危害女性健康。随着对卵巢癌基因分子层面认识的加深,以及靶向药物、抗体偶联药物、免疫治疗、热灌注化学药物疗法等逐渐应用于临床,卵巢癌的精准治疗手段也越来越丰富;对于难治、复发、耐药的卵巢癌,也取得了长足的进展。卵巢上皮性癌是卵巢恶性肿瘤中最常见的一类,本文回顾总结2023年度国际肿瘤会议中卵巢癌研究相关的进展,并对2023年度卵巢上皮性癌研究结果进行盘点,以期服务于临床诊疗和实践。Ovarian cancer is a highly malignant disease affecting female reproductive system.A great advances has happened in ovarian cancer entity with the deepening understanding of the molecular profile of ovarian cancer and the application of targeted therapy,antibody-conjugated drugs,immunotherapy,hyperthermic perfusion chemotherapy,etc.in clinical practice.Great progress has been made in precision treatments for ovarian cancer,especially in treatment of refractory,and drug-resistant ovarian cancer.Epithelial ovarian cancer is the most common type of ovarian malignant tumors.This article reviews the progress related to ovarian cancer research at the 2023 international conferences related with ovarian cancer.We selected the practice changing results from this year's ovarian cancer researches,aiming to a better performance of clinical diagnosis and treatment.

关 键 词：卵巢癌 卵巢上皮性癌 精准治疗 靶向治疗 抗体偶联药物 免疫治疗 热灌注化学药物疗法 

分 类 号：R737.31[医药卫生—肿瘤]